Abstract
Comments on "Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study".
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have